A hallmark of long-term memory formation is the requirement for protein synthesis. Administration of protein synthesis inhibitors impairs long-term memory formation without influencing short-term memory. Rapamycin is a specific inhibitor of target of rapamycin complex 1 (TORC1) that has been shown to block protein synthesis and impair long-term memory. In addition to regulating protein synthesis, TORC1 also phosphorylates Unc-51-like autophagy activating kinase-1 (Ulk-1) to suppress autophagy.
Long-term memory (memories lasting for days-to-weeks and longer), by comparison, is dependent on gene expression and protein synthesis that enhance the efficacy of specific neuronal circuit(s) by causing enhanced neurotransmitter release and morphological changes (e.g., formation of new synaptic connections; Abel & Klann, 2013; Alberini, 1999; Alberini & Kandel, 2015; Bailey, Kandel, & Harris, 2015; Knierim, 2015; Runyan & Dash, 2004; Sacktor, 2012; Sekeres, Neve, Frankland, & Josselyn, 2010) . Available amino acids, lipids, and other molecules are used as building blocks for these changes. These materials exist in readily accessible pools or can be derived from existing proteins (and/ or organelles). Existing proteins are primarily degraded by two intracellular catabolic systems, proteasomal degradation, and autophagy. The proteasome system degrades cellular proteins that have been tagged by ubiquitin. Previous studies have demonstrated the role of proteasome activity in memory formation in Aplysia and in rodents (Chain, Schwartz, & Hegde, 1999; Hegde et al., 1997; Lopez-Salon et al., 2001) . Autophagy is a lysosome-dependent degradation process that helps to maintain cellular homeostasis by degrading damaged or improperly folded proteins and protein aggregates. In addition, dysfunctional organelles such as mitochondria are also degraded and the proteins, lipids, and nucleotides recycled. However, the role of autophagy in memory formation has not been examined.
It has been demonstrated that impaired autophagic machinery can lead to the accumulation/aggregation of intracellular proteins and damaged organelles causing neurodegeneration (Lionaki, Markaki, Palikaras, & Tavernarakis, 2015; Menzies, Fleming, & Rubinsztein, 2015; Rubinsztein, 2006) . Three types of autophagy have been identified: chaperonemediated autophagy, microautophagy, and macroautophagy (Todde, Veenhuis, & van der Klei, 2009 ). Chaperone-mediated autophagy targets specific proteins (e.g., proteins containing KFERQ motifs) directly into the lysosome for degradation. It is thought that this process is activated during starvation and degrades proteins not critical for survival. Microautophagy involves the direct engulfment of cellular components by the lysosomes for degradation and is thought to play a role in recycling amino acids and other molecules. Macroautophagy (referred to hereafter as simply autophagy) is a regulated process that involves the formation of autophagosome, a double membrane vesicle that grows around and encapsulates cytoplasmic contents, including protein aggregates and damaged organelles. Autophagosome then fuse with endosomes and lysosomes, leading to degradation of the captured material.
Autophagy is initiated by dephosphorylation of Unc-51-like autophagy activating kinase 1 (Ulk-1), and is suppressed by the phosphorylation of Ulk-1 by the target of rapamycin complex 1 (TORC1). Dephosphorylated Ulk-1 leads to the nucleation and assembly of the initial phagophore membrane by the Beclin 1-class III phosphatidylinositol 3-kinase (class III PI3K) complex (Hara et al., 2008; Nazarko & Zhong, 2013) . The expansion and closure of the autophagosome is dependent on multiple proteins, including phosphatidylethanolamine-conjugated LC3 (LC3-II), which is generated from the cytosolic precursor LC3-I. The number of autophagosomes has been shown to correlate with the generation of LC3-II, and its levels have been widely used as a surrogate marker of autophagosome formation (Kabeya et al., 2000) . Our previous studies, and others, have shown that inhibition of TORC1 activity impairs protein translation and perturbs long-term memory formation (Dash et al., 2006; Stoica et al., 2011) . As impaired TORC1 activity has been shown to also increase autophagy, we hypothesized that behavioral training would suppress autophagy and that inhibition of autophagy would facilitate memory formation. Contrary to our expectations, we report that infusions of the autophagy inhibitors 3-MA and Spautin-1 into the hippocampus impair (whereas the autophagy activator peptide TAT-Beclin1 improves) spatial memory.
| M A TE RI A L S A ND M E THOD S

| Materials
Male Long-Evans rats (320-380 g; RRID:RGD_60991) were purchased from Charles River Laboratories. GFP-LC3 mice (Mizushima, Yamamoto, Matsui, Yoshimori, & Ohsumi, 2004; in a C57BL/6N background) were provided by the RIKEN BRC, through the National Bio-Resource Project of the MEXT (RRID:IMSR_RBRC00806). 3-methyladenine (3-MA) was obtained from Tocris (#3977). Spautin-1 was purchased from Cellagen Technology (#C3430). 
| Antibody characterization
The antibodies used in these experiments were verified for their immunoreactivity by western blotting against rat brain extracts. The apparent molecular weight and pattern of the immunoreactive band(s) was compared to previous publications. For LC3B (RRID:AB_2137707), bands corresponding to 16 kDa (LC3-II) and 18 kDa (LC3-1) were detected (Russo et al., 2011) . The Beclin-1 antibody (RRID:AB_ 490837) gave rise to a band of 60 kDa (Russo et al., 2011) , whereas PI3 kinase class III (RRID:AB_2299768) was detected at 100 kDa HYLIN ET AL. | 417 (Devereaux et al., 2013) . ß-Actin (RRID:AB_476697) was detected as a 42 kDa immunoreactive band (Simiczyjew, Mazur, Popow-Wozniak, Malicka-Blaszkiewicz, & Nowak, 2014) . The Atg16L1 antibody (RRID: AB_10950320) recognized two bands corresponding to approximately 65 and 70 kDa (Zhai et al., 2014) . Immunoreactivity for GFP (RRID:AB_ 298911) in the GFP-LC3 mice was compared to that seen in previous publications to ensure consistency in staining (Au, Bayir, Kochanek, & Clark, 2010) . No signal was detected in WT C57BL/6 mice lacking the GFP transgene.
| Animals
All protocols involving the use of animals were in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory 
| Intrahippocampal infusion and drug administration
Rats were used for infusion studies, as their relatively larger brain (compared to mice) makes it easier to accurately implant the guide cannulae, and to infuse the animals while awake. Rats were anesthetized with 5% isoflurane in a 1:1 N 2 O/O 2 mixture and then maintained with 2.5% isoflurane/1:1 air/O 2 mixture via face-mask.
Bilateral guide cannulas aimed at the dorsal hippocampus (anteroposterior, -3.8 mm from bregma; lateral, 6 2.0 mm from midline; ventral, -2.0 mm from the skull), were implanted. Rats were closely monitored during the recovery from surgery until full righting was restored. In addition, rats were monitored for any overt signs of pain such as vocalization and irritability prior to being returned to the vivarium. Rats were then allowed to recover in their home cages for 10 days. Rats were monitored and weighed daily and observed for fluid and food intake for the first five days after surgery. Signs of distress include labored respiration, lying on their side, lack of spontaneous movement, weight loss and/or vocalization to touch. Irritation at the incision site was treated topically with Tritop ointment.
After the 10-day recovery period, animals were randomly assigned to receive either the study drug or vehicle. Injection cannulas extended 1.85 mm beyond the tips of the guides, yielding a total depth of 3.85 mm below the skull. All injections (1.1 ml/hippocampus of either drug or vehicle) were performed in freely moving animals at a rate of 0.2 ml/min via dual syringe infusion pump. 3-MA was prepared in at stock concentrations of 180 mM in sterile saline. Spautin1 was prepared in DMSO then diluted in saline to a final concentration of 450 mM in 10% DMSO. After the completion of the behavioral experiments, cannulae placement was verified. No animals were removed from the study due to poor cannulae placement.
| Morris water maze
An experimenter who was kept blind to the treatment schedule performed all behavioral experiments. All of our behavioral experiments are carried out at the same time each day. Groups of animals were trained between 8-11 am or 2-5 pm. Animals trained in the morning were tested the following morning (24 hours post-training). Similarly, animals trained in the afternoon were tested the following afternoon.
For experiments to examine the behavioral consequences of intrahippocampal 3-MA infusion, a total of 20 rats were used (3MA: n 5 9; vehicle: n 5 11). For examining the effect of intrahippocampal Spautin-1 infusion, twenty-one rats were used (Spautin-1: n 5 10; vehicle:
n 5 11). One hour after drug (or vehicle) infusion, animals were trained in the hidden platform version of the Morris water maze task (Guzowski & McGaugh, 1997; Schenk & Morris, 1985) . Water maze training was carried out as a single block of 12 trials, with each trial separated by a period of 4 minutes. The platform remained in a constant position across all trials. Each trial started by placing the animal in one of four randomly chosen locations, facing the wall of the tank. Animals were allowed to search for the platform for 60 s. If an animal failed to find the platform, it was placed there by the experimenter. Animals were allowed to remain on the platform for a period of 30 s before being returned to a warming cage between trials. At 24 h after training, the animals were tested for memory retention by a probe trial in which the hidden platform was removed from the maze and the animals were allowed to search for a period of 60 s. Animals were monitored by a video camera linked to tracking software (Ethovision, Noldus; RRID:
For testing the consequences of intrahippocampal infusion of the TAT-Beclin1 peptide, rats received a block of ten trials, and two days later, another block of 4 trials (to ensure that all animals had learned and remember the location of the hidden platform). Immediately following the 4 reminder trials, rats were randomly assigned to receive bilateral infusions (1.0 ml/side @ 0.25 ml/min) of either 6.0ng TATBeclin-1 peptide (n 5 10) or an equimolar amount of TAT peptide alone (n 5 9). Twenty-four hours later, the time to find the hidden platform was recorded and used as an index of memory.
| Western blotting
To determine the effects of 3-MA and Spautin-1 in vivo, anesthetized rats were injected with study drug into one dorsal hippocampus (anteroposterior, -3.8 mm from bregma; lateral, 6 2.0 mm from midline; ventral, -3.85 mm from the skull) while vehicle was simultaneously infused into the contralateral hippocampus (n 5 4/group). Hippocampal punches (surrounding the site of infusion) were excised 3 hours after the infusion and protein extracts prepared. For all westerns except LC3, proteins were resolved in NuPAGE 4-12% Bis-Tris gels (Thermo Scientific, # NP0323PK2) and transferred to Immobilon-P PVDF membranes (Millipore, # IPVH00010). For LC3 western blots, proteins were resolved in 16% Novex Tris-Glycine gels. Membranes were blocked with 5% BSA in PBS-T (PBS 1 0.05% Tween 20) for 60 min at room temperature (RT). Membranes were incubated in primary antibodies diluted in PBST overnight at 4 8C. After extensive washing in PBST, membranes were incubated in species-specific secondary antibodies conjugated to horseradish peroxidase for 60 minutes at RT. Immunoreactivity was detected using an enhanced chemiluminescence (ECL) substrate and images captured using X-ray film. Optical densities of the resultant bands were quantified using ImageJ software (freely available from NIH; RRID:SCR_003070) and normalized against the levels of ß-Actin. Mean values for the vehicle controls were calculated and results presented as percent vehicle. Western blot results were replicated using at least two separate gels.
| Immunohistochemistry
Coronal brain sections (40 mm) were collected using a cryostat. Brain sections were incubated with primary antibodies overnight at 4 C in PBS containing 0.25% Triton X-100 with 2% BSA and 2.5% normal goat serum. Brain sections were extensively washed in PBST and then incubated for 1 hour in species-specific secondary antibodies conjugated to Alexa-fluors. Images were obtained using either a Zeiss Axiovert fluorescent microscope or a Zeiss LSM 510 confocal microscope.
Settings for image acquisition were maintained across images. Doublelabel immunohistochemistry was carried out as described above, with both primary antibodies incubated simultaneously. (RRID:AB_309685) was performed 2 weeks after training and testing) and was performed using three sections/animal from 5 randomly chosen animals/group.
| Quantification of autophagosomes
To examine the effect of water maze training on autophagosome numbers, transgenic mice expressing GFP-LC3 were utilized (Mizushima et al., 2004) . GFP-LC3 mice (n 5 4/group) were trained to criterion (three consecutive trials finding the platform in under 15 seconds) in the Morris water maze task to ensure learning. These mice were euthanized 15 minutes after training by sodium pentobarbital overdose followed by transcardial perfusion with 4% paraformaldehyde. A group of untrained GFP-LC3 littermates (n 5 4) were euthanized as described above and used as controls. Brains were removed and coronal tissue sections (corresponding to approximately -2.0 from bregma) selected for GFP immunohistochemistry. Two non-overlapping images of GFP immunoreactivity in the CA1/CA2 subfield (250 mm 2 ) were acquired from the dorsal hippocampus (3 sections each animal) from trained and untrained GFP-LC3 mice (n 5 4/group). Images were threshold adjusted using ImageJ. Studies have shown that autophagic-triggering stimuli cause aggregation of LC3-II on autophagosome membranes (Kabeya et al., 2000; Kouroku et al., 2007) . In GFP-LC3 mice, this results in GFP-LC3-decorated autophagosomes that can be detected using fluorescent microscopy. As previously described, we focused our analysis on structures within the cell soma or primary apical dendrite of CA1/CA2 pyramidal neurons that had a fluorescent intensity > 2 times the intensity of the dendrite, circular, and 0.5-2 mm in diameter. These parameters were used to identify GFP-LC3 puncta and are consistent with that recommended by Klionski et al., (Klionsky et al., 2016) . The total number of GFP-LC3 punta/250 mm 2 was counted and averaged across the two images/section by an experimenter blind to the group designations. The three sections per animal were averaged to give the number of GFP-LC3 punta/250 mm 2 for each animal.
| Statistical analysis
The number of animals used for each of the experiments is based on our prior experience with the techniques, and is consistent with that utilized by other laboratories (Blum, Moore, Adams, & Dash, 1999; Dash et al., 2006; Ge et al., 2010; Guzowski & McGaugh, 1997) . The behavioral studies presented in this manuscript were carried out using 9-11 animals/group. Using previously collected data (i.e., latency to platform during a probe trial, number of platform crossings), it was found that the standard deviation of the residuals could be anticipated to be between 16% and 21% of the mean. Assuming a minimally detectable effect size of 30% between 2 groups (drug and vehicle), the number of animals required to obtain statistical significance (with a power of 0.9 and an alpha value of 0.05) was found to range between 8-12 animals/group. For this reason, we utilized group sizes ranging from 9-11 animals to assess the behavioral consequences of manipulating autophagy. For our biochemistry measures (including counting autophagosomes after behavioral training), we utilized 4 animals/group. This is consistent with the results from a sample size calculation using preliminary western blot data which indicated that an n 5 4 would be 
| R E SU LTS
| Spatial learning increases GFP-LC3 punctae
It has been previously demonstrated that spatial learning induces molecular cascades in the CA1/CA2 subfield of the dorsal hippocampus (Blum et al., 1999) . To examine the influence of spatial learning on the number of autophagosomes in the CA1/CA2 subfield of the dorsal hippocampus, hemizygous GFP-LC3 mice (n 5 4/group) were used.
Mice were genotyped using DNA prepared from ear punches. The presence of the GFP-LC3 transgene was confirmed by RT-PCR as described in the methods section. Figure 1A shows that, as expected, primers 1 and 3 gave rise to a 350 bp product, indicative of wild-type.
Primers 1 and 2 give rise to a 250 bp product corresponding to the GFP-LC3 transgene. Hemizygous mice display both bands and were used for these studies. Hemizygous GFP-LC3 mice were trained in the Morris water maze to criterion, and then euthanized to examine GFP-LC3 puncta by immunohistochemistry. Representative confocal images of GFP staining in the CA1/CA2 apical dendrites from an untrained and a trained GFP-LC3 mouse are shown ( Figure 1B) . Colocalization of the GFP-LC3 signal with Atg16L (a component of the Atg5/Atg12 autophagosome complex) indicated that the observed GFP-LC3 puncta are likely autophagosome ( Figure 1C ). When the number of GFP-LC3
autophagosomes was counted, a significant increase was detected in trained GFP-LC3 mice compared to their untrained counterparts (Figure 1D ; two-tailed t-test, t 5 -3.849, n 5 4, p 5 0.012).
| Intrahippocampal administration of 3-MA or
Spautin-1 inhibits autophagy 3-MA, which blocks the formation of the autophagosome by inhibiting class III PI3K, has been widely used to study the role of autophagy (Petiot, Ogier-Denis, Blommaart, Meijer, & Codogno, 2000; Seglen & Gordon, 1982) . To test the consequences of intrahippocampal 3-MA, individual animals (n 5 6) were injected with 1.1 ml of 180 mM 3-MA to one hippocampus while an equal volume of vehicle (1.1 ml) was simultaneously infused into the contralateral hippocampus (allowing for a within subject comparison). Assuming a volume of 50 ml for the dorsal hippocampus, the equilibrium concentration of 3-MA after infusion is expected to be 3.9 mM. Cell culture studies that have used 3-MA to inhibit autophagy use doses from 4-20 mM (Steiger-Barraissoul & Rami, 2009; Wu et al., 2010) . Hippocampal punches (surrounding the site of infusion) were excised 3 hours after the infusion and protein extracts prepared. Western blots were carried out using ß-Actin as a loading control ( Figure 2A ). As each animal served as its own control, immunoreactivity was compared between the vehicle-and druginfused hippocampi using paired t-tests. For presentation purposes, the immunoreactivity of each drug-infused hippocampus was calculated as a percent of its paired vehicle-infused hippocampus. Spautin-1 is an inhibitor of autophagy that blocks the peptidase activity of Ubiquitin carboxyl-terminal hydrolase 10 (USP10) and Ubiquitin carboxyl-terminal hydrolase 13 (USP13), leading to increased ubiquitination and proteasomal degradation of Beclin-1-containing class III PI3K complexes (Liu et al., 2011) . To assess the in vivo consequences of Spautin-1 administration, Spautin-1 (1.1 ml of 450 mM) was injected into one hippocampus and the levels of class III PI3K, Beclin-1, and LC3-II compared to those seen in the vehicle (10% DMSO)
-injected contralateral hippocampus of the same animal (n 5 4; Figure   2C ). This dose of Spautin-1 is expected to reach an equilibrium concentration of 9.7 mM. Previous cell culture studies have used 10 mM Spautin-1 to inhibit autophagy (Shao et al., 2014) . Figure 2D shows that Spautin-1 modestly, but significantly, reduces the levels of class III PI3K (two-tailed t-test for paired variables, t 5 -3.366, n 5 4, p 5 0.044), Beclin-1 (two-tailed t-test for paired variables, t 5 -4.056, n 5 4, p 5 0.027), and the conversion of LC3-I to LC3-II (two-tailed ttest for paired variables, t 5 -5.473, n 5 4, p 5 0.012), after correction for loading using ß-Actin. 
| Inhibition of autophagy impairs long-term spatial memory
Based on the in vivo biochemical effects of 3-MA and Spautin-1, we next examined if these autophagy inhibitors can influence spatial learning or memory. Male Long Evans rats were implanted with guide cannulae aimed at the dorsal hippocampus and allowed to recover for 10 days. Animals were randomly assigned to receive either 3-MA (1.1 ml of 180 mM 3-MA/side; n 5 9) or vehicle (n 5 11). Bilateral infusions (at 0.20 ml/min) were carried out using infusion needles that extended 1.85 mm beyond the end of the guides. One hour after infusion, a single block of 12 training trials (separated by a 4 minutes ITI) was given in the Morris water maze task as described previously (Blum et al., 1999; Guzowski & McGaugh, 1997) by an experimenter blind to the treatment groups. For presentation purposes, the latency recorded for two trials was averaged. Figure 3A shows that the latency to locate the hidden platform did not significantly differ between the two groups over the course of training (two-way repeated measures ANOVA, F (1,18) 5 2.52, p 5 0.13), indicating no influence of the drug on learning.
Probe trials in which the hidden platform was removed from the tank and the animals allowed to search for a period of 60 sec were administered 24 hours after training. Time to first platform location ( Figure   3B ), and number of platform crossings ( Figure 3C ) are shown. The results show that 3-MA-infused animals required significantly more time to cross the location of the hidden platform (two-tailed t-test for unpaired variables, t 5 2.967, p 5 0.009) and crossed the platform significantly less frequently (Mann-Whitney Rank Sum Test, T 5 64, p 5 0.016), than did vehicle-infused controls. These differences were not attributable to differences in swimming speed (two-tailed t-test for unpaired variables, t 5 -0.117, p 5 0.908; Figure 3D ).
To examine the influence of Spautin-1 on hippocampusdependent learning and memory, cannulated rats were randomly assigned to be bilaterally infused with either Spautin-1 (1.1 ml of a 450 mM stock; n 5 10), or an equal volume of vehicle (n 5 11). After a 1-hour recovery period, animals were trained and tested in the water maze task as described above. Figure 4A shows that there was no significant difference in latency to locate the hidden platform over the course of training between the two groups (two-way repeated measures ANOVA F (1,19) 5 0.33, p 5 0.575). Quantification of probe trial performance (given 24 hours after training) revealed that Spautin-1 treated animals took significantly longer time to cross the previous location of the platform (two-tailed t-test for unpaired variables, t 5 -2.97; p 5 0.008; Figure 4B ) and crossed the platform less frequently (Mann-Whitney Rank Sum Test, T 5 81.50, p 5 0.034; Figure 4C ) than simultaneously tested, vehicle-infused animals. No significant   FIG URE 4 Intrahippocampal infusion of Spautin-1 impairs long-term spatial memory. a) Rats were given bilateral infusions of either Spautin-1 (1.1 ml of 450 mM stock/side; n 5 10) or vehicle (n 5 11). One hour later, rats were given 12 training trials in the abbreviated version of the Morris water maze task. Training data are presented as mean 6 SEM. Memory was tested 24 hours after training. Rats infused with Spautin-1 had impaired spatial memory as indicated by b) increased latency and c) fewer platform crossings. d) Swimming speed was not different between the Spautin-1-and vehicle-infused animals. Median for each data set is indicated by horizontal line. Error bars represent 90 th and 10 th percentile. *, p < 0.05. e) Representative photomicrographs showing activated astrocytes (immunostained with GFAP) in the cortex immediately adjacent to the cannulation site when examined 2 weeks postinfusion. Distal to the cannulation site, ramified "resting" astrocytes were observed. Scale bar, 100 mm. f) Representative photomicrographs of 2-week post-infusion hippocampi immunostained for NeuN (neurons), MAP2 (dendrites), and GFAP (astrocytes). No differences were observed between the vehicle-and Spautin-1-infused hippocampi. Scale bar, 1mm differences in swimming speed were detected between the two groups (two-tailed t-test for unpaired variables, t 5 -0.45, p 5 0.655; Figure 4D ).
As there is accumulating evidence of the interplay between autophagy and apoptosis, (Marino, Niso-Santano, Baehrecke, & Kroemer, 2014) it is possible that the memory-impairing effects of inhibiting autophagy we observed could be attributed to drug-induced neuronal loss and/or damage. To examine this possibility, sections from Spautin-1 infused animals (2 weeks post-infusion) were immunostained for NeuN (a marker of neurons), microtubule associated protein-2 (MAP2, a marker of dendrites), and glial fibrillary acidic protein (GFAP, a marker of astrocytes). Although immediately proximal to the cannulation site some reactive gliosis could be observed in the cortex ( Figure   4E ), this appeared to be injection injury-related as it was observed in in both the vehicle-and drug-infused animals. Figure 4F shows that no overt cell loss, dendritic damage, or gliosis was seen in either the vehicle or drug treated animals.
| Activation of autophagy improves memory
Previously, it has been shown that a peptide derived from the Golgiassociated plant pathogenesis-related protein 1 (GAPR-1) binding domain of Beclin-1 can activate autophagy by releasing Beclin-1 from the Beclin-GAPR-1 complex. In addition, when this peptide is attached to HIV-TAT (a cell penetrating peptide), it activates autophagy both in vitro and when administered to rodents (Shoji-Kawata et al., 2013) . In order to examine if this peptide can influence memory, cannulated rats were trained in the water maze. For this study, rats received a block of ten trials, and two days later, another block of 4 reminder trials to ensure that all rats had learned, and remember the location of, the platform ( Figure 5A ). Immediately following the 4 th reminder trial, rats were randomly assigned to one of two groups: TAT-Beclin1 peptide or TAT alone peptide. TAT-Beclin1 group received bilateral infusions (1.0 ml/side @ 0.25 ml/min) of 6.0 ng TAT-Beclin-1. Control animals received an equimolar amount of TAT peptide (1.0 ml/side of 2.5 ng).
We have previously utilized the TAT sequence as a control, and have not observed any demonstrable influences of this peptide on long-term memory (Blum & Dash, 2004) . Memory was tested 24 hours later.
Figure 5B shows that trained animals treated with TAT-Beclin-1 peptide found the hidden platform significantly faster (two-tailed t-test for unpaired variables, t 5 -2.284, p 5 0.036) than animals treated with TAT alone, suggesting enhanced memory.
After the completion of memory testing, animals were euthanized and brains examined for cannulae location. The representative image of a brain section (stained with cresyl violet) indicates the location of the infusion site (arrowheads; Figure 5C ). The summary data presented in Figure 5D shows that all animals used in this study had infusion sites (black circles) that terminated in the dorsal hippocampus.
| D I SCUSSION
Using pharmacological agents as a well as GFP-LC3 mice, we investi- To the best of our knowledge, this is the first study to implicate autophagy in memory formation.
3-MA is a widely used inhibitor of autophagy, whose mechanism of action has been linked to its ability to inhibit class III PI3K (Seglen & Gordon, 1982) . However, recent studies have revealed that 3-MA has differential effects on autophagy (i.e., activating or inhibiting) depending on the cellular context and duration of exposure. These effects are thought to be due to its ability to potently, but transiently inhibit class III PI3K (thereby inhibiting autophagy) while persistently inhibiting class I PI3K (thereby activating autophagy; Wu et al., 2010) . In addition, 3-MA has been found to stimulate PKA (via its capacity to increase intracellular cAMP levels) in adipocytes (Heckmann, Yang, Zhang, & Liu, | 423 2013). Although this effect has not been examined in neurons, an increase in cAMP levels would be anticipated to improve long-term memory, (Barad, Bourtchouladze, Winder, Golan, & Kandel, 1998) an effect opposite to that observed here. Due to these potentially confounding actions of 3-MA, we verified our findings using specific and potent autophagy inhibitor-1 (Spautin-1). Spautin-1 has been shown to directly and potently inhibit the peptidase activity of UPS10 and UPS13, resulting in increased Beclin 1 and class III PI3K ubiquitination and degradation (Liu et al., 2011) . Consistent with this, we observed that Spautin-1 reduces Beclin-1 and class III PI3K levels. As no other mechanisms of action have been identified for Spautin-1, its ability to also impair long-term memory provides further evidence of a role for autophagy in memory. Of interest, neither 3-MA nor Spautin-1 influenced learning, which indicates that these autophagy inhibitors do not cause aberrant neuronal activity nor cell death. Consistent with this, histopathological analysis did not reveal any visible cell loss/damage in Spautin-1-treated animals as compared to vehicle controls ( Figure 4) .
A recent report has demonstrated that restoration of autophagic flux is sufficient to improve memory in animals exposed to chronic unpredictable stress (Gu et al., 2014) . In aging, reduced autophagic flux is thought to cause accumulation of dysfunctional or damaged molecules/organelles, leading to age-related memory decline, (Gkikas, Petratou, & Tavernarakis, 2014) an effect that can be alleviated by activation of autophagy. For example, in aged Drosophilla, spermidineinduced autophagy reduces the aggregation of ubiquitinated proteins and improves memory (Gupta et al., 2013) . Using TgCRND8 mice (a model of Alzheimer's disease), Yang et al. (2011) found that increasing autophagic-lysosomal function reduced the accumulation of ß-amyloid deposits and prevented the development of memory dysfunction.
While these and other studies have demonstrated a critical role for autophagy in pathologies that are associated with memory dysfunction, the present study is, to the best of our knowledge, the first to observe a training-related increase in autophagosome formation and ascribe a role for autophagy in long-term memory formation in normal animals.
A large body of evidence supports the premise that long-term memory requires the synthesis of new proteins for synaptic remodeling and morphological changes (Bourtchuladze et al., 1994; Dash, Hochner, & Kandel, 1990; Kandel et al., 2014; Sacktor, 2012) . One function of autophagy is to degrade cellular proteins to generate amino acids that can be used for subsequent protein synthesis (Glick, Barth, & Macleod, 2010; Shen & Ganetzky, 2009) . Thus, it is plausible that the degradation of proteins by autophagy is required for recycling proteins for new protein synthesis. Alternatively, autophagy can selectively degrade molecules that repress memory (e.g., transcriptional repressors) thereby facilitating long-term memory formation (Shehata, Matsumura, OkuboSuzuki, Ohkawa, & Inokuchi, 2012) . This suggests that stimulation of autophagy may be beneficial for long-term memory formation. Consistent with this possibility, we found that intrahippocampal administration of the autophagy activator TAT-Beclin-1 enhances spatial long-term memory ( Figure 5 ). At present, however, it is not known if autophagy plays a general role in protein recycling for protein synthesis and synapse formation, or if specific proteins are targeted for autophagy that facilitate memory formation. Further, as only male animals were used in order to provide proof-in-principle evidence that autophagy plays a role in memory formation, it is not known if this role differs between males and females. These questions will need to be the subject of future studies.
